SynthesisEuropean journal of clinical pharmacology2026
The association between proton pump inhibitor use and the risk of mortality in patients with kidney disease: a systematic review and meta-analysis.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUse of proton pump inhibitor (PPI) has been associated with adverse health outcomes, including increased risk of all-cause mortality. Evidence suggests that individuals with kidney disease who use PPIs may experience higher mortality, though the nature of this association is not well established.
objectiveTo assess the relationship between PPI use and mortality among individuals with kidney disease through a systematic review and meta-analysis.
methodsA comprehensive search of Ovid-MEDLINE, Ovid-EMBASE, and Cochrane CENTRAL was conducted through April 2025 to identify randomized controlled trials and observational studies examining mortality among PPI users versus non-users with kidney disease. Both unadjusted mortality rates and adjusted hazard ratios (aHRs) were extracted. A random-effects meta-analysis was performed using the Hartung-Knapp-Sidik-Jonkman method, with the Sidik-Jonkman estimator used for between-study variance (τ
resultsThe review included 24 observational studies encompassing 216,032 individuals with kidney disease. Across 20 cohorts from 17 observational studies, mortality was 23.2% among PPI users and 22.1% among non-users. Pooled adjusted estimates from 18 studies (20 cohorts) indicated a significantly increased risk of death in PPI users (aHR 1.26; 95% CI, 1.11-1.42). Considerable heterogeneity was observed, but subgroup analyses revealed consistent trends.
conclusionsOur meta-analysis showed that PPI use was linked to elevated mortality risk in kidney disease populations. Careful consideration is advised when prescribing PPIs, and further research is needed.
Indexed as
Identifiers
41792514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.